JAK inhibitors should be last-resort for high-risk patients: TGA safety alert
The TGA has issued a safety warning over Janus kinase inhibitor use in high-risk patients with chronic inflammatory conditions after a post-market study showed an…
Tag: JAK inhibitors
A new topical option for vitiligo in the wings?
Studies show improvement in repigmentation over a year, investigators report.
JAK inhibitor ‘highly effective’ for alopecia areata
Trial participants taking the oral biologic had significantly improved hair regrowth and adverse events were largely mild.
Second COVID-19 vax ‘needs to be timely’ in RA
Antibody titres are much lower in patients on DMARDs, researchers find.
Atopic dermatitis: Baricitinib ‘shows long-term efficacy’
An extension study shows response to the oral janus kinase inhibitor can be maintained for 16 months in about half of responders.
